Abstract:Background: Hantaviruses - dichotomized into New World (i.e. Andes virus, ANDV; Sin Nombre virus, SNV) and Old-World viruses (i.e. Hantaan virus, HTNV) - are zoonotic viruses transmitted from rodents to humans. Currently, no FDA-approved vaccines against hantaviruses exist. Given the recent breakthrough to human-human transmission by the ANDV, an essential step is to establish an effective pandemic preparedness infrastructure to rapidly identify cell tropism, infective potential, and effective therapeutic agents through systematic investigation. Methods: We established human cell model systems in lung (airway and distal lung epithelial cells), heart (pluripotent stem cell-derived (PSC-) cardiomyocytes), and brain (PSC-astrocytes) cell types and subsequently evaluated ANDV, HTNV and SNV tropisms. Transcriptomic, lipidomic and bioinformatic data analyses were performed to identify the molecular pathogenic mechanisms of viruses in different cell types. This cell-based infection system was utilized to establish a drug testing platform and pharmacogenomic comparisons. Results: ANDV showed broad tropism for all cell types assessed. HTNV replication was predominantly observed in heart and brain cells. ANDV efficiently replicated in human and mouse 3D distal lung organoids. Transcriptomic analysis showed that ANDV infection resulted in pronounced inflammatory response and downregulation of cholesterol biosynthesis pathway in lung cells. Lipidomic profiling revealed that ANDV-infected cells showed reduced level of cholesterol esters and triglycerides. Further analysis of pathway-based molecular signatures showed that, compared to SNV and HTNV, ANDV infection caused drastic lung cell injury responses. A selective drug screening identified STING agonists, nucleoside analogues and plant-derived compounds that inhibited ANDV viral infection and rescued cellular metabolism. In line with experimental results, transcriptome data shows that the least number of total and unique differentially expressed genes were identified in urolithin B- and favipiravir-treated cells, confirming the higher efficiency of these two drugs in inhibiting ANDV, resulting in host cell ability to balance gene expression to establish proper cell functioning. Conclusions: Overall, our study describes advanced human PSC-derived model systems and systems-level transcriptomics and lipidomic data to better understand Old and New World hantaviral tropism, as well as drug candidates that can be further assessed for potential rapid deployment in the event of a pandemic.

An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid As a Potential Antiviral Therapeutic Against Hantavirus Infection

Dihydropyridine-derived calcium channel blocker as a promising anti-hantavirus entry inhibitor

In-Cell Western Assays to Evaluate Hantaan Virus Replication As a Novel Approach to Screen Antiviral Molecules and Detect Neutralizing Antibody Titers

Comparative Analysis of Molecular Pathogenic Mechanisms and Antiviral Development Targeting Old and New World Hantaviruses

Molecular insight into the neutralization mechanism of human-origin monoclonal antibody AH100 against Hantaan virus

Development of Small-Molecule Inhibitors Against Hantaviruses.

Study on the Recombinant Expression of Hantaan Virus Protein N and the Establishment and Application of Rnp-Igm Direct Capture ELISA

A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus

Synthesis and biological evaluation of baloxavir marboxil analogs for the treatment of influenza A (H<sub>1</sub>N<sub>1</sub>) virus

25-Hydroxycholesterol inhibits Hantavirus infection by reprogramming cholesterol metabolism

Pathogenicity of novel hantavirus isolate and antigenicity and immunogenicity of novel strain-based inactivated vaccine

Efficient rescue of a newly classified Ebinur lake orthobunyavirus with GFP reporter and its application in rapid antiviral screening

A nanoluciferase SFTSV for rapid screening antivirals and real-time visualization of virus infection in mice

Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics

High throughput profiling identified PA-L106R amino acid substitution in A(H1N1)pdm09 influenza virus that confers reduced susceptibility to baloxavir in vitro

High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2

An algal lectin griffithsin inhibits Hantaan virus infection in vitro and in vivo

In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean–Congo hemorrhagic fever virus

Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection

Single dose recombinant VSV based vaccine elicits robust and durable neutralizing antibody against Hantaan virus

Two point mutations in protocadherin-1 disrupt hantavirus recognition and afford protection against lethal infection